Cassidy Bio

🗓 Founded 2024👥 22 employees💰 Last funded Aug 2024
Biotechnology Research🌐 cassidybio.com
Website LinkedIn
Cassidy Bio is an AI-first biotechnology company building the first programmable platform for gene editing. Cassidy Bio replaces the narrow, trial-and-error design process with large-scale prediction, simulation, and in silico validation, powered by genomic foundation models trained on proprietary biological data. The platform scales to connect across multiple components guides, editing systems, delivery systems and variant backgrounds ranking designs by safety and efficacy. Cassidy Bio’s vision is to enable not just one-off miracles, but a new generation of reliable gene editing therapies at scale.
2
Total investors
1
Early stage
0
Mid stage
0
Late stage
2024
Founded

Investors

2 investors
All
Early stage
Mid stage
Late stage
Investor geography2 countries
Israel
1
Denmark
1
Frequently asked questions
Who invested in Cassidy Bio?
Cassidy Bio has 2 investors on record on gritt.io, including 1 early-stage backers.
When did Cassidy Bio last raise funding?
The most recent investment in Cassidy Bio recorded on gritt.io was in August 2024.
When was Cassidy Bio founded?
Cassidy Bio was founded in 2024.
What industry is Cassidy Bio in?
Cassidy Bio operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.